A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  European Neuropsychopharmacology

• Publication date

  2008-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.EURONEURO.2007.06.003PMID 17683917
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gates

  2008cited by this paper
• Placental transfer of quetiapine in relation to P-glycoprotein activity

  2007cited by this paper
• Genetics. SNPs, silent but not invisible.

  2007cited by this paper
• Pharmacokinetics of fexofenadine enantiomers in healthy subjects.

  2007cited by this paper
• SNPs, Silent But Not Invisible

  2007cited by this paper
• A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity

  2007cited by this paper
• Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy.

  2006cited by this paper
• The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases

  2006cited by this paper
• ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline.

  2006cited by this paper
• Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp)

  2006cited by this paper
• Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier.

  2006cited by this paper
• THE INFLUENCE OF P-GLYCOPROTEIN ON CEREBRAL AND HEPATIC CONCENTRATIONS OF NORTRIPTYLINE AND ITS METABOLITES

  2006cited by this paper
• Lack of Association between the C3435T Polymorphism in the Human Multidrug Resistance (MDR1) Gene and Response to Antiepileptic Drug Treatment

  2005cited by this paper
• Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833.

  2005cited by this paper
• P‐glycoprotein interaction with risperidone and 9‐OH‐risperidone studied in vitro, in knock‐out mice and in drug–drug interaction experiments

  2005influential reference
• THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL

  2005influential reference
• Basic transthoracic echocardiography

  2005cited by this paper
• Modulation of p-Glycoprotein Transport Function at the Blood-Brain Barrier

  2005cited by this paper
• Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"?

  2005cited by this paper
• Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans

  2005cited by this paper
• Influence of P‐glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood–brain barrier

  2005influential reference
• Population pharmacokinetic analysis of drug–drug interactions among risperidone, bupropion, and sertraline in CF1 mice

  2005cited by this paper
• Pharmacokinetic Analysis of the Blood-Brain Barrier Transport of 125I-Amyloid β Protein 40 in Wild-Type and Alzheimer's Disease Transgenic Mice (APP,PS1) and Its Implications for Amyloid Plaque Formation

  2005cited by this paper
• Quantitative in Vivo Microdialysis Study on the Influence of Multidrug Transporters on the Blood-Brain Barrier Passage of Oxcarbazepine: Concomitant Use of Hippocampal Monoamines as Pharmacodynamic Markers for the Anticonvulsant Activity

  2005cited by this paper
• Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site.

  2005cited by this paper
• Clinical aspects of the MDR1 (ABCB1) gene polymorphism.

  2004cited by this paper
• In Situ Transport of Vinblastine and Selected P-glycoprotein Substrates: Implications for Drug-Drug Interactions at the Mouse Blood-Brain Barrier

  2004cited by this paper
• Ultrastructural localization of P-glycoprotein on capillary endothelial cells in human gliomas

  2004cited by this paper
• The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.

  2004cited by this paper
• P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline

  2004cited by this paper
• The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein.

  2004cited by this paper
• Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures.

  2004influential reference
• Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy

  2004cited by this paper
• Association of genetic loci

  2004cited by this paper
• Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers

  2004cited by this paper
• P-glycoprotein structure and evolutionary homologies

  2004cited by this paper
• Neuronal and Glial Expression of the Multidrug Resistance Gene Product in an Experimental Epilepsy Model

  2004cited by this paper
• Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats.

  2004cited by this paper
• Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity.

  2004cited by this paper
• Neuronal MDR-1 Gene Expression and Persistent Low Levels of Anticonvulsants in a Child with Refractory Epilepsy

  2004cited by this paper
• Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy

  2004cited by this paper
• ABC transporters and the blood-brain barrier.

  2004cited by this paper
• Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1).

  2004cited by this paper
• Identification of P‐glycoprotein substrates and inhibitors among psychoactive compounds — implications for pharmacokinetics of selected substrates

  2004influential reference
• Olanzapine Penetration into Brain is Greater in Transgenic Abcb1a P-glycoprotein-Deficient Mice than FVB1 (Wild-Type) Animals

  2004cited by this paper
• Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance

  2004cited by this paper
• Use of Loperamide as a Phenotypic Probe of mdr1a Status in CF-1 Mice

  2004cited by this paper
• Quantitative characterization of direct P‐glycoprotein inhibition by St John's wort constituents hypericin and hyperforin

  2004cited by this paper
• Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood–brain barrier of Abcb1a gene knockout mice

  2004cited by this paper
• Effect of P‐glycoprotein inhibition on methadone analgesia and brain distribution in the rat

  2004cited by this paper
• Importance of P-glycoprotein at blood-tissue barriers.

  2004cited by this paper
• No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects

  2003cited by this paper
• Role of P-Glycoprotein in Pharmacokinetics

  2003cited by this paper
• abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice.

  2003cited by this paper
• Investigation of polymorphism in the MDR1 gene and antidepressant-induced mania

  2003cited by this paper
• Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption.

  2003cited by this paper
• Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.

  2003cited by this paper
• How Does the Benzamide Antipsychotic Amisulpride get into the Brain?—An In Vitro Approach Comparing Amisulpride with Clozapine

  2003influential reference
• Efflux transporters of the human placenta.

  2003cited by this paper
• Respiratory and miotic effects of morphine in healthy volunteers when P‐glycoprotein is blocked by quinidine

  2003cited by this paper
• Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs.

  2003cited by this paper
• Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity.

  2003cited by this paper
• Modulation of the multidrug resistance (MDR) system in the nematode Haemonchus contortus by changing cholesterol content: effects on resistance to anthelmintics.

  2003cited by this paper
• Inhibition of P-Glycoprotein by Newer Antidepressants

  2003influential reference
• Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy.

  2002cited by this paper
• P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats.

  2002cited by this paper
• Penetration of Endogenous Steroid Hormones Corticosterone, Cortisol, Aldosterone and Progesterone into the Brain is Enhanced in Mice Deficient for Both mdr1a and mdr1b P‐Glycoproteins

  2002cited by this paper
• Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P‐glycoprotein

  2002cited by this paper
• In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.

  2002influential reference
• A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression

  2002cited by this paper
• Extrapyramidal Symptoms with Ritonavir/Indinavir Plus Risperidone

  2002cited by this paper
• Expression of P-Glycoprotein in Human Cerebral Cortex Microvessels

  2002cited by this paper
• Effect of St John's wort on the pharmacokinetics of fexofenadine

  2002cited by this paper
• P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice.

  2002cited by this paper
• Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects

  2002cited by this paper
• Reversible Coma Caused By Risperidone-Ritonavir Interaction

  2002cited by this paper
• Drugs as P-glycoprotein substrates, inhibitors, and inducers

  2002cited by this paper
• P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells.

  2001cited by this paper
• Isolation of endothelial cells from brain, lung, and kidney: expression of the multidrug resistance P-glycoprotein isoforms.

  2001cited by this paper
• In Vivo Evidence for P‐Glycoprotein–Mediated Transport of Phenytoin at the Blood–Brain Barrier of Rats

  2001cited by this paper
• Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood–brain barrier

  2001cited by this paper
• Inhibition of P-Glycoprotein Transport Function by Grapefruit Juice Psoralen

  2001influential reference
• Rational use of in vitro P-glycoprotein assays in drug discovery.

  2001cited by this paper
• From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance

  2001cited by this paper
• Cytochrome P450 2D6 Genotype and Methadone Steady-State Concentrations

  2001cited by this paper
• P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain

  2001cited by this paper
• Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene.

  2001cited by this paper
• Effect of mdr1a P-Glycoprotein Gene Disruption, Gender, and Substrate Concentration on Brain Uptake of Selected Compounds

  2001cited by this paper
• In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.

  2001cited by this paper
• Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique.

  2000cited by this paper
• Increased drug delivery to the brain by P‐glycoprotein inhibition

  2000cited by this paper
• Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation.

  2000influential reference
• Penetration of Amitriptyline, but Not of Fluoxetine, into Brain is Enhanced in Mice with Blood-Brain Barrier Deficiency Due to Mdr1a P-Glycoprotein Gene Disruption

  2000cited by this paper
• The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice.

  2000cited by this paper
• Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

  2000cited by this paper
• Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.

  2000cited by this paper
• Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates

  2000cited by this paper
• Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium.

  1999cited by this paper
• Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat.

  1999cited by this paper
• Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier.

  1999cited by this paper

• Eutectic-based self-emulsifying drug delivery system for enhanced oral delivery of risperidone

  2025cites this paper
• Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies.

  2024cites this paper
• The Benzoxazole Heterocycle: A Comprehensive Review of the Most Recent Medicinal Chemistry Developments of Antiproliferative, Brain-Penetrant, and Anti-inflammatory Agents

  2024cites this paper
• Contrasting ABCB1 pharmacogenetics and psychotropic responses in child and adolescent psychiatry: a case comparison.

  2023cites this paper
• Impact of Sex and Genetic Variation in Relevant Pharmacogenes on the Pharmacokinetics and Safety of Valsartan, Olmesartan and Hydrochlorothiazide

  2023cites this paper
• [11C]metoclopramide is a sensitive radiotracer to measure moderate decreases in P-glycoprotein function at the blood-brain barrier

  2023cites this paper
• Potential of nanostructured lipid carriers in oral delivery of the poorly soluble drugs

  2023cites this paper
• Investigating the multi-target pharmacological mechanism of wendan decoction in the treatment of schizophrenia

  2023cites this paper
• Effects of Nicotine Exposure From Tobacco Products and Electronic Cigarettes on the Pathogenesis of Neurological Diseases: Impact on CNS Drug Delivery

  2022cites this paper
• Overcoming the blood–brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches

  2022cites this paper
• Recent Synergy of Nanodiamonds: Role in Brain-Targeted Drug Delivery for the Management of Neurological Disorders

  2022cites this paper
• Influence of MDR1 gene polymorphism (2677G>T) on expression and function of P-glycoprotein at the blood-brain barrier: utilizing novel P-glycoprotein humanized mice with mutation.

  2022cites this paper
• ABCB1 variants and sex affect serotonin transporter occupancy in the brain

  2022cites this paper
• An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use

  2022cites this paper
• Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations.

  2021cites this paper
• Investigation on P-Glycoprotein Function and Its Interacting Proteins under Simulated Microgravity

  2021cites this paper
• Antipsychotic medication for women with schizophrenia spectrum disorders

  2021cites this paper
• Brain/blood ratios of methadone and ABCB1 polymorphisms in methadone-related deaths

  2021cites this paper
• The association between interleukin-8 gene-251 A/T polymorphism and sepsis

  2021cites this paper
• Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression.

  2021cites this paper
• Effects of ABCB1 gene polymorphism on the efficacy of antidepressant drugs

  2021cites this paper
• Modification of the association between paroxetine serum concentration and SERT-occupancy by ABCB1 (P-glycoprotein) polymorphisms in major depressive disorder

  2020cites this paper
• The Role of P-Glycoprotein at the Blood–Brain Barrier in Neurological and Psychiatric Disease

  2020cites this paper
• Association between 8 P‐glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug‐induced hyperprolactinaemia

  2020cites this paper
• [PET imaging to study the functional impact of P-glycoprotein in neuropharmacokinetics].

  2020cites this paper
• Frontiers in Neuroscience Imaging: Whole-Body PET.

  2020cites this paper
• Epigenetics of Glioblastoma Multiforme: From Molecular Mechanisms to Therapeutic Approaches.

  2020cites this paper
• In Silico Prediction of P-glycoprotein Binding: Insights from Molecular Docking Studies.

  2019cites this paper
• Pharmacogenetics of Antidepressants: from Genetic Findings to Predictive Strategies

  2019cites this paper
• Neuroprotective Potential of Curcumin-Loaded Nanostructured Lipid Carrier in an Animal Model of Alzheimer’s Disease: Behavioral and Biochemical Evidence

  2019cites this paper
• Photoacoustic molecular imaging using combined acupuncture and gold nanorods as a composite contrast agent

  2019cites this paper
• A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia

  2019cites this paper
• Pharmacokinetics of Single Doses of Methadone and Buprenorphine in Blood and Oral Fluid in Healthy Volunteers and Correlation With Effects on Psychomotor and Cognitive Functions.

  2019cites this paper
• Interactions between artemisinin derivatives and P-glycoprotein.

  2019cites this paper
• Paliperidona palmitato: cuando la innovación galénica mejora los resultados clínicos de la molécula

  2019cites this paper
• Role of pharmacokinetic and pharmacodynamic parameters in neuroadaptations induced by drugs of abuse, with a focus on opioids and psychostimulants.

  2019cites this paper
• P-Glycoprotein on Blood-Brain Barrier Plays a Vital Role in Fentanyl Brain Exposure and Respiratory Toxicity in Rats

  2018cites this paper
• Coadministration of antiepileptic drugs and P-glycoprotein inhibitors of flavonoid-type

  2018cites this paper
• ABCB1 and CYP2D6 polymorphisms and treatment response of psychotic patients in a naturalistic setting

  2018cites this paper
• Brain Delivery of Curcumin Using Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Preparation, Optimization, and Pharmacokinetic Evaluation.

  2018cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2018influential citation
• Effect of levetiracetam on rocuronium duration in patients undergoing cerebrovascular surgery

  2018cites this paper
• Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing.

  2018cites this paper
• Blood–Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies

  2017cites this paper
• Managing interactions between cognitive enhancers and other psychotropics

  2017cites this paper
• Trifluoperazine, a novel autophagy inhibitor, increases radiosensitivity in glioblastoma by impairing homologous recombination

  2017influential citation
• Effect of P-glycoprotein Mediated Inhibition in Drug Bioavailability

  2017cites this paper
• The effects of dietary and herbal phytochemicals on drug transporters☆

  2017cites this paper
• The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid–Antipsychotic Drug Interactions

  2017cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2017influential citation
• P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo.

  2016cites this paper
• Nanostructured lipid carriers: versatile oral delivery vehicle

  2016cites this paper
• Increasing BMI is associated with reduced expression of P-glycoprotein (ABCB1 gene) in the human brain with a stronger association in African Americans than Caucasians

  2016cites this paper
• Clinically Significant Interactions with Antipsychotics

  2016cites this paper
• Trifluoperazine: A Sprightly Old Drug.

  2016cites this paper
• P-glikoprotein ve Tedaviye Dirençteki Rolü

  2016cites this paper
• Association of ABCB1 Gene Polymorphisms with Efficacy and Adverse Reaction to Risperidone or Paliperidone in Han Chinese Schizophrenic Patients

  2016influential citation
• The ABCB1, rs9282564, AG and TT Genotypes and the COMT, rs4680, AA Genotype are Less Frequent in Deceased Patients with Opioid Addiction than in Living Patients with Opioid Addiction

  2016cites this paper
• ABCB1 genotyping in the treatment of depression.

  2016cites this paper
• Quercetin as an Augmentation Agent in Schizophrenia.

  2016cites this paper
• Glioblastoma multiforme: Pathogenesis and treatment.

  2015cites this paper
• Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report

  2015cites this paper
• Liposomes Coloaded with Elacridar and Tariquidar To Modulate the P-Glycoprotein at the Blood-Brain Barrier.

  2015cites this paper
• Flavonoid compounds as reversal agents of the P-glycoprotein-mediated multidrug resistance: biology, chemistry and pharmacology

  2015influential citation
• Problèmes posés par la consommation des benzodiazépines chez les personnes âgées : focus sur la mémoire

  2015cites this paper
• The Mefloquine Intoxication Syndrome: A Significant Potential Confounder in the Diagnosis and Management of PTSD and Other Chronic Deployment-Related Neuropsychiatric Disorders

  2015cites this paper
• Designing CNS Drugs for Optimal Brain Exposure

  2015cites this paper
• Quantitative Estimation of P-glycorptein-Mediated Drug Transport by Mechanistically Modeled Intrinsic Clearance

  2015cites this paper
• U.F.R. DES SCIENCES PHARMACEUTIQUES

  2015cites this paper
• Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature

  2015cites this paper
• Bioanalytical method validation of Venlafaxine and Desvenlafaxine in mouse plasma, brain and liver using a MEPS/HPLC assay: a path to study these drugs’ intranasal administration

  2015influential citation
• Nanoencapsulation Improves Relative Bioavailability and Antipsychotic Effect of Olanzapine in Rats.

  2015cites this paper
• P-glikoprotein ve Tedaviye Dirençteki Rolü P-glycoprotein and its Role in Treatment Resistance

  2015cites this paper
• Case Studies of Non‐CNS Drugs to Minimize Brain Penetration—Nonsedative Antihistamines

  2015cites this paper
• How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example.

  2015cites this paper
• A systematic microdialysis study of dopamine transmission in the accumbens shell/core and prefrontal cortex after acute antipsychotics

  2015cites this paper
• Improved brain uptake of peptide-based CNS drugs via alternative routes of administrations of its nanocarrier delivery systems: a promising strategy for CNS targeting delivery of peptides

  2014cites this paper
• Imaging histamine receptors using PET and SPECT

  2014cites this paper
• Coadministration of P-Glycoprotein Modulators on Loperamide Pharmacokinetics and Brain Distribution

  2014cites this paper
• The Role of P-Glycoprotein in Psychiatric Disorders and in Psychiatric Treatment

  2014cites this paper
• Effect of ATP-Binding Cassette Transporters on Antipsychotics-Induced Cytotoxicity in Blood Brain Barrier Endothelial Cells

  2014influential citation
• Mechanisms of P-glycoprotein alteration during anticancer treatment: role in the pharmacokinetic and pharmacological effects of various substrate drugs.

  2014cites this paper
• Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose.

  2014cites this paper
• ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition

  2014cites this paper
• 抗がん剤治療時における P-glycoproteinの発現・機能変動と薬物動態並びに薬理作用へ及ぼす影響

  2014cites this paper
• Pharmacological role of efflux transporters: Clinical implications for medication use during breastfeeding

  2014cites this paper
• Nanoencapsulation of olanzapine increases its efficacy in antipsychotic treatment and reduces adverse effects.

  2014cites this paper
• Edoxaban population pharmacokinetics and exposure–response analysis in patients with non-valvular atrial fibrillation

  2014cites this paper
• DMD055566 700..706

  2014cites this paper
• The Pharmacological Role and Clinical Applications of Antipsychotics' Active Metabolites: Paliperidone versus Risperidone

  2013cites this paper
• Alteration in P‐glycoprotein at the blood–brain barrier in the early period of MCAO in rats

  2013cites this paper
• Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment.

  2013cites this paper
• Epigenetic pathways and glioblastoma treatment

  2013cites this paper
• Understanding depot antipsychotics: an illustrated guide to kinetics

  2013cites this paper
• Clinically Significant Drug Interactions with Atypical Antipsychotics

  2013cites this paper
• Blood-CNS transport mechanisms in pathophysiology and drug delivery

  2013cites this paper
• Genetically Engineered Animals in Product Discovery and Development

  2013cites this paper
• Membrane Transporters in ADME

  2013cites this paper
• Psychiatric Drug-Drug Interactions

  2013cites this paper
• Co-administration of P-glycoprotein modulators on loperamide pharmacokinetics and brain distribution

  2013cites this paper